The 3-year OS in lymphoma patients was 71% (95% CI, 59–80%) in the Plerixafor Group and 84% (95% CI, 76–89%) in the G-CSF Group (p = 0.1) (Figure 2). This evidence concerns the gene CSF3 and lymphoma.